Gamgee
Two-person startup building personalized mRNA cancer vaccines for dogs.
On the record
Checkpoint: Window closes if Gamgee has not filed a USDA CVB regulatory pre-submission
The call
Gamgee owns a viral single-dog story and borrowed lab access, while FidoCure owns the clinics, the data, and no technical reason not to add mRNA.
Gamgee uses artificial intelligence to design custom messenger RNA vaccines that train each dog's immune system to fight its own cancer. The company has one strong case study (a dog named Rosie whose tumor shrank by 75 percent) but that is not enough proof yet. The hard part should be manufacturing and getting government approval to sell the vaccine, but Gamgee is borrowing those capabilities from university partners instead of building them in house, which means another company could do the same thing. FidoCure already serves 143 veterinary clinics and has data on two billion dog treatments, so they could add mRNA vaccine technology in one to three years and instantly become the bigger player. The one thing that could change this is if Gamgee's early patient trials show that the vaccine works consistently in more dogs beyond Rosie, or if they lock in their own manufacturing and distribution deals before FidoCure moves.
Why
01
AI pressure: ChatGPT, AlphaFold, and similar consumer AI tools. The founder used public AI tools to design the vaccine, so any competitor can copy that computational step today. Could AI do the core job? Yes, likely.
02
Bigger players: FidoCure (One Health Company). FidoCure already has 143+ clinics, an IDEXX partnership, and a 2B-datapoint dataset; it just hasn't added mRNA yet. Could a giant copy it? Yes, easily.
03
What protects it. Early manufacturing access through UNSW and UQ academic labs, if that arrangement stays exclusive to Gamgee.
What would change this call
FidoCure announces an mRNA product line or partnership within 12 to 24 months. Would show the incumbent closing Gamgee's technical gap and eliminating its window.
Gamgee files a USDA CVB or APVMA regulatory pre-submission within 12 months. Would show Gamgee converting its single case into a real regulatory pathway.
Published outcomes from a controlled cohort of 15 to 20 dogs beyond Rosie. Would show whether the vaccine's tumor response generalizes or was a one-off result.
Gamgee files a USDA CVB or APVMA regulatory pre-submission within 12 months. Would show Gamgee converting its single case into a real regulatory pathway.
Published outcomes from a controlled cohort of 15 to 20 dogs beyond Rosie. Would show whether the vaccine's tumor response generalizes or was a one-off result.
Key numbers
- Rosie's tumor shrank about 75% after custom mRNA vaccine
- Gamgee has 2 employees
- FidoCure operates in 143+ clinics with 2B+ datapoints
Named risks
- Sole traction is one uncontrolled case; one of Rosie's tumors did not respond and needed redesign.
- FidoCure or IDEXX-adjacent partner could add mRNA capability within 12-36 months and close the window.
- Manufacturing and regulatory access are borrowed from UNSW and University of Queensland, not owned.
- Regulatory approval historically takes years, as ELIAS's decade-long USDA path shows.
- Per-case unit economics below $5K COGS unproven; pricing model undisclosed.
Rivals, as read in July 2026
| Rival | Direction | Evidence |
|---|---|---|
| FidoCure | contesting | 143+ clinic network and IDEXX distribution as of 2026 but no mRNA product shipped yet |
| Torigen | contesting | Commercial vaccine with published clinical data, CEO publicly criticized Gamgee's Rosie case on 2026-04-02 |
| ELIAS Animal Health | gaining on | Achieved full USDA CVB approval for autologous canine vaccine in March 2025 after a decade |
| ImpriMed | contesting | Offers personalized canine lymphoma drug-response prediction as an adjacent modality |
Questions people ask
- Is Gamgee profitable in 2026?
- No. Gamgee is pre-revenue with 2 employees as of July 2026, per Y Combinator's directory. It is in the S2026 batch running clinical trials in Australia and has disclosed no revenue, customer counts, or pricing model, only a single viral case study as its main traction signal.
- Could AI replace what Gamgee does?
- The design layer, using ChatGPT, AlphaFold, Grok and Gemini for genomic analysis, is fully reproducible with public tools, as founder Paul Conyngham demonstrated in December 2025 with no biology degree. The wet-lab manufacturing and regulatory approval steps, borrowed from UNSW and University of Queensland, are not AI-automatable.
- Who is Gamgee's biggest competitor?
- FidoCure (One Health Company), a YC W2018 alumnus, claims a network of 143+ clinics and 180+ vet oncologists plus a 2B-plus-datapoint dataset and a US patent for AI-driven precision therapy as of July 2026 (vendor-claimed). It uses small-molecule drugs, not mRNA, but has no structural bar to adding it.
- Who owns Gamgee?
- Gamgee is privately held and founder-led by Paul Conyngham, a Sydney-based data engineer, and is backed by Y Combinator as part of its Summer 2026 (S2026) batch. No separate priced round, valuation, or outside institutional investor has been publicly disclosed as of July 2026.
- Has Gamgee's dog cancer vaccine actually been proven to work?
- Evidence is limited to one uncontrolled case: founder Paul Conyngham's dog Rosie showed roughly 75% tumor shrinkage within weeks of a custom mRNA vaccine in December 2025, reported March 15, 2026. One of Rosie's tumors did not respond and needed a redesigned vaccine; no controlled cohort data exists yet.
- What's the biggest risk to Gamgee's survival?
- FidoCure, an incumbent with 143+ clinics and an IDEXX distribution partnership as of 2026, has every infrastructure piece needed to add an mRNA product line and no structural blocker stopping it, creating an estimated 12 to 36 month window before Gamgee's niche closes.
Timeline
- 2026-07-25YC directory lists Gamgee with 2 employees, active, accepting cases globally
- 2026-06-22ABC News Australia reports regulatory red tape barrier for scaling treatment
- 2026-04-02Torigen CEO publicly questions rigor of Gamgee's viral Rosie case
- 2026-03-15Multiple outlets report Rosie's tumor shrank ~75% after AI-designed mRNA vaccine
- 2025-12Founder's dog Rosie treated with custom mRNA cancer vaccine in Australia
- 2025-04-18Competitor ELIAS Animal Health gets full USDA approval after over a decade
- 2025-02-08Competitor Vetigenics closes $6M seed round in animal-health biotech
Revision history
27 July 2026
First assessed. Losing its protection. The text above is fixed as of this date and is not edited afterwards.
In the same band
Sources
- A man with no biology degree used ChatGPT to help build his dog a cancer vaccine. It worked. (2026-03-15)
- Biotech Startups funded by Y Combinator (YC) 2026 (2026-07-25)
- Australian Tech Founder Uses ChatGPT and AlphaFold to Design Dog Cancer Vaccine, Tumours Shrink by 75% (2026-03-15)
- An Australian tech entrepreneur used AI to help create the first-ever bespoke cancer vaccine for a dog (2026-03-15)
- Torigen CEO on what the viral cancer story reveals about pet immunotherapy (2026-04-02)
- Watching his dog slowly die, techie refused to give up. Then he used AI and created a custom 'cancer vaccine' (2026-03-15)
- Oncology Startups funded by Y Combinator (YC) 2026 (2026-07-25)
- Novel, targeted canine cancer therapy receives US patent (2026-03-11)
- USDA approves KC biotech startup's secret weapon in the fight against cancer in dogs (2025-04-18)
- Gamgee: Scalable Personalised Cancer Treatment (2026-07-25)
- Homepage (2026-07-25)
- Healthcare Startups funded by Y Combinator (YC) 2026 (2026-07-22)